New drug challenges standard in breast cancer showdown
NCT ID NCT07416253
First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests a new drug, trastuzumab-rezetecan, against an approved one, T-DXd, in women with early or locally advanced HER2-positive breast cancer. About 68 participants will get one of the two drugs before surgery to see which leads to more tumor disappearance. The goal is to find a better option to control the disease before the main treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.